Viewing Study NCT06597734


Ignite Creation Date: 2025-12-25 @ 2:22 AM
Ignite Modification Date: 2026-01-07 @ 4:09 AM
Study NCT ID: NCT06597734
Status: RECRUITING
Last Update Posted: 2025-10-09
First Post: 2024-09-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module